Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in methotrexate-naive active rheumatoid arthritis
2004-003295-10Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Dec 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of golimumab and methotrexate in rheumatoid arthritis (RA) (4 arms), sponsored by Janssen Biotech. Primary endpoints: ACR50 at Week 24 and Change from baseline in van der Heijde Modified Sharp score at Week 52. Started Dec 2005; status: completed.
02
Drugs
golimumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-003295-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003295-10.